Followers | 144 |
Posts | 10941 |
Boards Moderated | 0 |
Alias Born | 04/02/2006 |
Tuesday, April 18, 2017 4:47:02 PM
April 18, 2017 20:05 UTC
Exelixis to Release First Quarter 2017 Financial Results on Monday, May 1, 2017
- Conference Call and Webcast to Follow at 5:00 p.m. EDT/ 2:00 p.m. PDT -
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NASDAQ: EXEL) announced today that its first quarter 2017 financial results will be released on Monday, May 1, 2017 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call to discuss the results and provide a general business update. The conference call will be accessible via the Internet from the company’s website.
To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under Investors & Media. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call (855) 793-2457 (domestic) or (631) 485-4921 (international) and provide the conference call passcode 3901622 to join by phone.
A telephone replay will be available until 8:00 p.m. EDT on May 3, 2017. Access numbers for the telephone replay are: 855-859-2056 (domestic) and 404-537-3406 (international); the passcode is 3901622. A webcast replay will also be archived on www.exelixis.com for one year.
About Exelixis
Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since its founding in 1994, three products discovered at Exelixis have progressed through clinical development, received regulatory approval, and entered the marketplace. Two are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL and VEGF receptors: CABOMETYX™ tablets approved for previously treated advanced kidney cancer and COMETRIQ® capsules approved for progressive, metastatic medullary thyroid cancer. The third product, COTELLIC®, is a formulation of cobimetinib, a selective inhibitor of MEK, is marketed under a collaboration with Genentech (a member of the Roche Group), and is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a variety of forms of cancer and are the subjects of broad clinical development programs. For more information on Exelixis, please visit www.exelixis.com or follow @ExelixisInc on Twitter.
Exelixis, the Exelixis logo, COMETRIQ and COTELLIC are registered U.S. trademarks, and CABOMETYX is a U.S. trademark.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170418006451/en/
Contacts
Exelixis, Inc.
Susan Hubbard, 650-837-8194
Executive Vice President
Public Affairs & Investor Relations
shubbard@exelixis.com
Recent EXEL News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/13/2024 08:03:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 08:05:43 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/08/2024 08:11:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/07/2024 10:19:20 PM
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May • Business Wire • 05/07/2024 08:05:00 PM
- Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update • Business Wire • 04/30/2024 08:05:00 PM
- Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024 • Business Wire • 04/16/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:59:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:58:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:58:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:58:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:58:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:58:01 PM
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March • Business Wire • 02/27/2024 09:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2024 11:33:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 10:08:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 12:21:07 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/13/2024 02:19:48 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/06/2024 09:49:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 09:28:36 PM
- Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update • Business Wire • 02/06/2024 09:05:00 PM
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February • Business Wire • 02/01/2024 09:05:00 PM
- Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024 • Business Wire • 01/25/2024 01:00:00 PM
- Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024 • Business Wire • 01/23/2024 09:05:00 PM
FEATURED POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • May 14, 2024 10:09 AM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM